ProCE Banner Activity

CE / CME

Cases and Challenges in the Optimal Treatment of Triple-Negative BC

Text Module

Review the latest developments in how to care for patients with triple-negative breast cancer (TNBC) throughout the disease course with this interactive text module sharing insights from Jeremy Force, DO.

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacology credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Released: May 08, 2023

Expiration: May 07, 2024

Share

Faculty

Jeremy M. Force

Jeremy M. Force, DO

Assistant Professor
Department of Medicine
Division of Medical Oncology
Breast Oncology Program
Duke University
Durham, North Carolina

Provided by

Provided by Partners for Advancing Clinical Education (PACE)

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc. and Merck Sharp & Dohme Corp.

Gilead Sciences, Inc.

Target Audience

NPs, PAs, and nurses who specialize in oncology

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe rationale for and appropriate use of newer therapies in current standards of care for early and advanced TNBC

  • Integrate evidence-based advances into care of patients with TNBC

  • Employ proven strategies to recognize and mitigate toxicities of newer therapies to support optimal outcomes 

Disclosure

Partners for Advancing Clinical Education (PACE) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Jeremy M. Force, DO

Assistant Professor
Department of Medicine
Division of Medical Oncology
Breast Oncology Program
Duke University
Durham, North Carolina

Jeremy Force, DO: consultant/advisor/speaker: Exact Science, G1 Therapeutics, Onclive, PRIME.

The planners and content peer reviewers from Partners for Advancing Clinical Education and Practicing Clinicians Exchange do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from May 08, 2023, through May 07, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

The program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

ANCC Credit Designation
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.00 contact hour, including 1.00 hour of pharmacology credit.

 

AAPA Credit Designation

Joint AccreditationPartners for Advancing Clinical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

 

 

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credits for learning and change.